Nectar Lifesciences Publishes Q4 & FY26 Financial Results
Nectar Lifesciences Limited announced its audited financial results for the quarter and year ended March 31, 2026. For the year, total income was ₹16,337.32 Lakhs and net loss was ₹53,765.51 Lakhs. For the quarter, total income was ₹5,691.96 Lakhs and net loss was ₹13,008.90 Lakhs. EPS for the year was ₹(11.72).
The announcement of financial results is material for investors. The reported losses, while negative, are a routine disclosure for listed companies. The impact is medium as it provides clarity on the company's financial health.
The company reported a significant net loss for both the quarter and the full financial year, indicating a negative financial performance.
Nectar Lifesciences Limited has published its audited financial results for the quarter and financial year ended March 31, 2026. The results were published in the Business Standard (English) and Desh Sewak (Punjabi) newspapers on June 1, 2026.
The company reported significant financial figures for the period. Total income from continuing operations for the year ended March 31, 2026, was ₹16,337.32 Lakhs. For the same period, Net Profit/(Loss) after tax and after exceptional items from continuing operations was ₹(29,288.48) Lakhs. The Net Profit/(Loss) after tax and after exceptional items from discontinued operations stood at ₹(23,554.37) Lakhs. The total profit/(loss) for the period from continuing and discontinued operations was ₹(53,765.51) Lakhs.
For the quarter ended March 31, 2026, Total Income from continuing operations was ₹5,691.96 Lakhs. The Net Profit/(Loss) after tax and after exceptional items from continuing operations was ₹(7,320.58) Lakhs, while from discontinued operations, it was ₹(3,071.20) Lakhs. The total profit/(loss) for the quarter was ₹(13,008.90) Lakhs.
Earnings per share (EPS) for the year ended March 31, 2026, was ₹(11.72) for basic and diluted continuing operations. For the quarter ended March 31, 2026, basic and diluted EPS from continuing operations was ₹(2.85). The company's paid-up share capital was ₹1,942.61 Lakhs, and other equity excluding revaluation reserve was ₹56,288.19 Lakhs as of March 31, 2026.
What to do with a filing like this
Nectar Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nectar Lifesciences Limited. Read the original for the full detail.